Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1866 1
1937 1
1938 1
1939 1
1940 2
1942 3
1943 1
1944 1
1945 2
1946 1
1947 1
1948 4
1949 1
1950 3
1951 3
1952 2
1953 4
1954 3
1956 1
1957 3
1958 4
1959 8
1960 3
1961 6
1962 7
1963 4
1964 14
1965 9
1966 6
1967 7
1968 6
1969 10
1970 15
1971 15
1972 29
1973 15
1974 19
1975 20
1976 22
1977 23
1978 25
1979 27
1980 29
1981 36
1982 31
1983 44
1984 52
1985 60
1986 74
1987 51
1988 57
1989 59
1990 75
1991 84
1992 92
1993 75
1994 77
1995 105
1996 88
1997 102
1998 114
1999 126
2000 144
2001 150
2002 143
2003 162
2004 190
2005 219
2006 230
2007 238
2008 198
2009 224
2010 246
2011 296
2012 288
2013 299
2014 301
2015 321
2016 334
2017 363
2018 373
2019 311
2020 383
2021 256
Text availability
Article attribute
Article type
Publication date

Search Results

6,827 results
Results by year
Filters applied: . Clear all
Page 1
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.
Attal M, Richardson PG, Rajkumar SV, San-Miguel J, Beksac M, Spicka I, Leleu X, Schjesvold F, Moreau P, Dimopoulos MA, Huang JS, Minarik J, Cavo M, Prince HM, Macé S, Corzo KP, Campana F, Le-Guennec S, Dubin F, Anderson KC; ICARIA-MM study group. Attal M, et al. Among authors: anderson kc. Lancet. 2019 Dec 7;394(10214):2096-2107. doi: 10.1016/S0140-6736(19)32556-5. Epub 2019 Nov 14. Lancet. 2019. PMID: 31735560 Clinical Trial.
Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma.
Richardson PG, Oriol A, Larocca A, Bladé J, Cavo M, Rodriguez-Otero P, Leleu X, Nadeem O, Hiemenz JW, Hassoun H, Touzeau C, Alegre A, Paner A, Maisel C, Mazumder A, Raptis A, Moreb JS, Anderson KC, Laubach JP, Thuresson S, Thuresson M, Byrne C, Harmenberg J, Bakker NA, Mateos MV; HORIZON (OP-106) Investigators. Richardson PG, et al. Among authors: anderson kc. J Clin Oncol. 2021 Mar 1;39(7):757-767. doi: 10.1200/JCO.20.02259. Epub 2020 Dec 9. J Clin Oncol. 2021. PMID: 33296242 Free article.
Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma.
Dimopoulos MA, Jakubowiak AJ, McCarthy PL, Orlowski RZ, Attal M, Bladé J, Goldschmidt H, Weisel KC, Ramasamy K, Zweegman S, Spencer A, Huang JSY, Lu J, Sunami K, Iida S, Chng WJ, Holstein SA, Rocci A, Skacel T, Labotka R, Palumbo A, Anderson KC. Dimopoulos MA, et al. Among authors: anderson kc. Blood Cancer J. 2020 Feb 13;10(2):17. doi: 10.1038/s41408-020-0273-x. Blood Cancer J. 2020. PMID: 32054831 Free PMC article. Review.
Tutorial: guidance for quantitative confocal microscopy.
Jonkman J, Brown CM, Wright GD, Anderson KI, North AJ. Jonkman J, et al. Among authors: anderson ki. Nat Protoc. 2020 May;15(5):1585-1611. doi: 10.1038/s41596-020-0313-9. Epub 2020 Mar 31. Nat Protoc. 2020. PMID: 32235926 Review.
Timing the initiation of multiple myeloma.
Rustad EH, Yellapantula V, Leongamornlert D, Bolli N, Ledergor G, Nadeu F, Angelopoulos N, Dawson KJ, Mitchell TJ, Osborne RJ, Ziccheddu B, Carniti C, Montefusco V, Corradini P, Anderson KC, Moreau P, Papaemmanuil E, Alexandrov LB, Puente XS, Campo E, Siebert R, Avet-Loiseau H, Landgren O, Munshi N, Campbell PJ, Maura F. Rustad EH, et al. Among authors: anderson kc. Nat Commun. 2020 Apr 21;11(1):1917. doi: 10.1038/s41467-020-15740-9. Nat Commun. 2020. PMID: 32317634 Free PMC article.
Centrosome anchoring regulates progenitor properties and cortical formation.
Shao W, Yang J, He M, Yu XY, Lee CH, Yang Z, Joyner AL, Anderson KV, Zhang J, Tsou MB, Shi H, Shi SH. Shao W, et al. Among authors: anderson kv. Nature. 2020 Apr;580(7801):106-112. doi: 10.1038/s41586-020-2139-6. Epub 2020 Mar 25. Nature. 2020. PMID: 32238932 Free PMC article.
Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria.
Balwani M, Sardh E, Ventura P, Peiró PA, Rees DC, Stölzel U, Bissell DM, Bonkovsky HL, Windyga J, Anderson KE, Parker C, Silver SM, Keel SB, Wang JD, Stein PE, Harper P, Vassiliou D, Wang B, Phillips J, Ivanova A, Langendonk JG, Kauppinen R, Minder E, Horie Y, Penz C, Chen J, Liu S, Ko JJ, Sweetser MT, Garg P, Vaishnaw A, Kim JB, Simon AR, Gouya L; ENVISION Investigators. Balwani M, et al. Among authors: anderson ke. N Engl J Med. 2020 Jun 11;382(24):2289-2301. doi: 10.1056/NEJMoa1913147. N Engl J Med. 2020. PMID: 32521132 Clinical Trial.
Blockade of the Phagocytic Receptor MerTK on Tumor-Associated Macrophages Enhances P2X7R-Dependent STING Activation by Tumor-Derived cGAMP.
Zhou Y, Fei M, Zhang G, Liang WC, Lin W, Wu Y, Piskol R, Ridgway J, McNamara E, Huang H, Zhang J, Oh J, Patel JM, Jakubiak D, Lau J, Blackwood B, Bravo DD, Shi Y, Wang J, Hu HM, Lee WP, Jesudason R, Sangaraju D, Modrusan Z, Anderson KR, Warming S, Roose-Girma M, Yan M. Zhou Y, et al. Among authors: anderson kr. Immunity. 2020 Feb 18;52(2):357-373.e9. doi: 10.1016/j.immuni.2020.01.014. Epub 2020 Feb 11. Immunity. 2020. PMID: 32049051 Free article.
6,827 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page